Terms ending in 2033
Every in-force patent on Astellas Pharma Inc.'s record whose computed term ends in 2033, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,085,540 | Pyrazinecarboxamide Compound In force · High confidence | Astellas Pharma Inc. | In force | High confidence | |
| US 9,127,055 | Method of Treating Pain with Anti-Human NGF Antibody In force · High confidence | Astellas Pharma Inc. | In force | High confidence | |
| US 9,481,911 | Methods for Detecting FGFR3/TACC3 Fusion Genes In force · High confidence | Astellas Pharma Inc. | In force | High confidence | |
| US 10,004,739 | Methods for Treating Cancer by Inhibiting FGFR3/TACC3 Fusion Protein In force · High confidence | Astellas Pharma Inc. | In force | High confidence | |
| US 9,447,090 | Imidazopyridine Compounds In force · High confidence | Astellas Pharma Inc. | In force | High confidence | |
| US 9,433,675 | Combination Therapy Involving Antibodies Against Claudin 18.2 for Treatment of Cancer In force · High confidence | Astellas Pharma Inc. | In force | High confidence | |
| US 10,022,444 | Combination Therapy Involving Antibodies Against Claudin 18.2 for Treatment of Cancer In force · High confidence | Astellas Pharma Inc. | In force | High confidence | |
| US 10,813,996 | Combination Therapy Involving Antibodies Against Claudin 18.2 for Treatment of Cancer In force · Low confidence | Astellas Pharma Inc. | In force | Low confidence | |
| US 11,839,689 | Formulations of Enzalutamide In force · Low confidence | Medivation Prostate Therapeutics LLC | In force | Low confidence | |
| US 12,447,128 | Formulations of Enzalutamide In force · High confidence | Astellas Pharma Inc. | In force | High confidence | |
| 3 more term ends in 2033 · Pro | |||||
10 of 13 patents shown. Soonest term end first, then patent number.
Pro members see all 13.
11 of these are in force and held by Astellas Pharma Inc..
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.